House Subcommittee Approves $2.1 Billion for FDA - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

House Subcommittee Approves $2.1 Billion for FDA


ePT--the Electronic Newsletter of Pharmaceutical Technology

Washington, DC (June 26)—The US Food and Drug Administration will have a $2.1 billion budget next year if the fiscal year 2009 bill markup by the US House of Representatives’ Agriculture Appropriations Subcommittee passes through Congress. The subcommittee approved for FDA $282 million above the President’s budget request for FY 2009.

In her opening statement at last week’s meeting, Subcommittee Chairwoman Rosa DeLauro (D-CT) noted that the administration had recently made a request for an additional $275 million for FDA [see full story]. “To be sure, this is a long overdue acknowledgment that the status quo is not working when it comes to our broken food safety system,” she said. “So we are indeed, eager to fully fund that request and provide the critical resources necessary for reform.”

DeLauro added her concern that the administration has yet to indicate how FDA should use these additional funds. “…Real reform requires real management – so this committee will convene hearings and require spending reports to ensure the money is used as effectively as possible,” she said.

The marked-up Subcommittee bill goes to the House Appropriations Committee next where it will be further reviewed and marked up before going to the full House of Representatives.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here